483 related articles for article (PubMed ID: 15780433)
1. Glucagon-like peptide 1 and its derivatives in the treatment of diabetes.
Nauck MA; Meier JJ
Regul Pept; 2005 Jun; 128(2):135-48. PubMed ID: 15780433
[TBL] [Abstract][Full Text] [Related]
2. Glucagon-like peptide 1 (GLP-1) in the treatment of diabetes.
Nauck MA
Horm Metab Res; 2004; 36(11-12):852-8. PubMed ID: 15655719
[TBL] [Abstract][Full Text] [Related]
3. Incretin mimetics as emerging treatments for type 2 diabetes.
Joy SV; Rodgers PT; Scates AC
Ann Pharmacother; 2005 Jan; 39(1):110-8. PubMed ID: 15562141
[TBL] [Abstract][Full Text] [Related]
4. Therapies for the treatment of type 2 diabetes mellitus based on incretin action.
Gallwitz B
Minerva Endocrinol; 2006 Jun; 31(2):133-47. PubMed ID: 16682937
[TBL] [Abstract][Full Text] [Related]
5. Glycaemic effects of incretins in Type 1 diabetes mellitus: a concise review, with emphasis on studies in humans.
Dupre J
Regul Pept; 2005 Jun; 128(2):149-57. PubMed ID: 15780434
[TBL] [Abstract][Full Text] [Related]
6. The potential role of glucagon-like peptide 1 in diabetes.
Meier JJ; Nauck MA
Curr Opin Investig Drugs; 2004 Apr; 5(4):402-10. PubMed ID: 15134281
[TBL] [Abstract][Full Text] [Related]
7. [Analogs of glucagon-like peptide-1 (GLP-1): an old concept as a new treatment of patients with diabetes mellitus type 2].
Diamant M; Bunck MC; Heine RJ
Ned Tijdschr Geneeskd; 2004 Sep; 148(39):1912-7. PubMed ID: 15495988
[TBL] [Abstract][Full Text] [Related]
8. Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM.
Rachman J; Barrow BA; Levy JC; Turner RC
Diabetologia; 1997 Feb; 40(2):205-11. PubMed ID: 9049482
[TBL] [Abstract][Full Text] [Related]
9. Glucagon-like peptide-1 as a treatment option for type 2 diabetes and its role in restoring beta-cell mass.
Gallwitz B
Diabetes Technol Ther; 2005 Aug; 7(4):651-7. PubMed ID: 16120042
[TBL] [Abstract][Full Text] [Related]
10. Subcutaneous glucagon-like peptide-1 improves postprandial glycaemic control over a 3-week period in patients with early type 2 diabetes.
Todd JF; Edwards CM; Ghatei MA; Mather HM; Bloom SR
Clin Sci (Lond); 1998 Sep; 95(3):325-9. PubMed ID: 9730852
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic potential of glucagon-like peptide 1 in type 2 diabetes.
Nauck M
Diabet Med; 1996 Sep; 13(9 Suppl 5):S39-43. PubMed ID: 8894470
[TBL] [Abstract][Full Text] [Related]
12. [Glucagon-like peptide-1(GLP-1)].
Wasada T
Nihon Rinsho; 2004 Jun; 62(6):1175-80. PubMed ID: 15206160
[TBL] [Abstract][Full Text] [Related]
13. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.
Neumiller JJ
J Am Pharm Assoc (2003); 2009; 49 Suppl 1():S16-29. PubMed ID: 19801361
[TBL] [Abstract][Full Text] [Related]
14. Glucagon-like peptide 1(GLP-1) in biology and pathology.
Meier JJ; Nauck MA
Diabetes Metab Res Rev; 2005; 21(2):91-117. PubMed ID: 15759282
[TBL] [Abstract][Full Text] [Related]
15. Glucagon-like peptide 1: evolution of an incretin into a treatment for diabetes.
D'Alessio DA; Vahl TP
Am J Physiol Endocrinol Metab; 2004 Jun; 286(6):E882-90. PubMed ID: 15140755
[TBL] [Abstract][Full Text] [Related]
16. The incretin system and its role in type 2 diabetes mellitus.
Holst JJ; Vilsbøll T; Deacon CF
Mol Cell Endocrinol; 2009 Jan; 297(1-2):127-36. PubMed ID: 18786605
[TBL] [Abstract][Full Text] [Related]
17. The entero-insular axis in type 2 diabetes--incretins as therapeutic agents.
Creutzfeldt W
Exp Clin Endocrinol Diabetes; 2001; 109 Suppl 2():S288-303. PubMed ID: 11460578
[TBL] [Abstract][Full Text] [Related]
18. Incretins: a new treatment option for type 2 diabetes?
Geelhoed-Duijvestijn PH
Neth J Med; 2007 Feb; 65(2):60-4. PubMed ID: 17379930
[TBL] [Abstract][Full Text] [Related]
19. Incretins and other peptides in the treatment of diabetes.
Todd JF; Bloom SR
Diabet Med; 2007 Mar; 24(3):223-32. PubMed ID: 17263764
[TBL] [Abstract][Full Text] [Related]
20. The multifaceted potential of glucagon-like peptide-1 as a therapeutic agent.
Lam NT; Kieffer TJ
Minerva Endocrinol; 2002 Jun; 27(2):79-93. PubMed ID: 11961501
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]